Disc Medicine (IRON) – Research Analysts’ Recent Ratings Updates

Disc Medicine (NASDAQ: IRON) has recently received a number of price target changes and ratings updates:

• 10/21/2026 – Disc Medicine had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $149.00 price target on the stock.
• 10/20/2026 – Disc Medicine had its price target raised by Morgan Stanley from $90.00 to $92.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – Disc Medicine had its price target raised by Wells Fargo & Company from $86.00 to $124.00. They now have an “overweight” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Truist Financial Corporation from $83.00 to $115.00. They now have a “buy” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by BMO Capital Markets from $100.00 to $120.00. They now have an “outperform” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Wedbush from $100.00 to $110.00. They now have an “outperform” rating on the stock.
• 10/19/2026 – Disc Medicine had its price target raised by Cantor Fitzgerald from $125.00 to $170.00. They now have an “overweight” rating on the stock.
• 10/17/2026 – Disc Medicine was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/15/2026 – Disc Medicine had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/16/2026 – Disc Medicine had its price target raised by Wells Fargo & Company from $79.00 to $86.00. They now have an “overweight” rating on the stock.
• 9/12/2026 – Disc Medicine was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/10/2026 – Disc Medicine had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
• 9/10/2026 – Disc Medicine had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/10/2026 – Disc Medicine had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $128.00 price target on the stock.
• 9/10/2026 – Disc Medicine had its “outperform” rating reaffirmed by Wedbush. They now have a $100.00 price target on the stock.
• 9/2/2026 – Disc Medicine had its price target raised by Wedbush from $88.00 to $100.00. They now have an “outperform” rating on the stock.
• 9/1/2026 – Disc Medicine had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/29/2026 – Disc Medicine was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In related news, COO Jonathan Yu sold 8,796 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at approximately $4,515,410.88. The trade was a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John D. Quisel sold 33,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $17,892,965.60. This represents a 12.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 173,046 shares of company stock worth $13,591,034 over the last ninety days. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.